{"filing":{"accession_number":"0001213900-26-084255","cik":"0001949257","ticker":"RDPTF","company_name":"Radiopharm Theranostics Ltd","form":"6-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"ea0300222-6k_radiopharm.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1949257/000121390026084255/ea0300222-6k_radiopharm.htm"},"events":[{"id":23150,"run_id":20949,"accession_number":"0001213900-26-084255","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This is an ASX application for quotation of 408,839,531 ordinary fully paid shares issued on 3 August 2026 as Tranche 1 of an Australian placement at AUD 0.015 per share. The document references a prior Appendix 3B announcement dated 24 July 2026 describing a \"Proposed issue of securities\" placement. This represents a material dilutive equity issuance raising approximately AUD 6.1 million, with additional tranches and warrants yet to be issued to complete the transaction, typical of a capital raise by a smaller biotech company.","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-08-03","form":"6-K","submitted_at":null,"items":[{"id":23304,"accession_number":"0001213900-26-084255","item_number":"EX-99.1","item_title":"ea030022201ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is an ASX application for quotation of 408,839,531 ordinary fully paid shares issued on 3 August 2026 as Tranche 1 of an Australian placement at AUD 0.015 per share. The document references a prior Appendix 3B announcement dated 24 July 2026 describing a \"Proposed issue of securities\" placement. This represents a material dilutive equity issuance raising approximately AUD 6.1 million, with additional tranches and warrants yet to be issued to complete the transaction, typical of a capital raise by a smaller biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:36:40.926430+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23304,"accession_number":"0001213900-26-084255","item_number":"EX-99.1","item_title":"ea030022201ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is an ASX application for quotation of 408,839,531 ordinary fully paid shares issued on 3 August 2026 as Tranche 1 of an Australian placement at AUD 0.015 per share. The document references a prior Appendix 3B announcement dated 24 July 2026 describing a \"Proposed issue of securities\" placement. This represents a material dilutive equity issuance raising approximately AUD 6.1 million, with additional tranches and warrants yet to be issued to complete the transaction, typical of a capital raise by a smaller biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:36:40.926430+00:00","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-08-03"}]}